News articles about TrovaGene (NASDAQ:TROV) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. TrovaGene earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.7576940327182 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of TrovaGene (TROV) traded up $0.01 during midday trading on Friday, reaching $0.31. 4,355,138 shares of the company were exchanged, compared to its average volume of 2,466,625. The firm has a market cap of $15.58, a PE ratio of -0.30 and a beta of 0.35. TrovaGene has a 12-month low of $0.23 and a 12-month high of $2.40.

TrovaGene (NASDAQ:TROV) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. The firm had revenue of $0.12 million for the quarter. TrovaGene had a negative net margin of 7,960.05% and a negative return on equity of 259.94%. sell-side analysts anticipate that TrovaGene will post -0.78 EPS for the current year.

TROV has been the topic of a number of research reports. Maxim Group cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th. Finally, HC Wainwright initiated coverage on shares of TrovaGene in a research note on Thursday, December 21st. They issued a “buy” rating and a $1.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. TrovaGene presently has an average rating of “Hold” and a consensus price target of $3.70.

TRADEMARK VIOLATION NOTICE: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/12/30/trovagene-trov-getting-somewhat-favorable-news-coverage-accern-reports.html.

About TrovaGene

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.